We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sun Pharmaceuticals has reported financials for the first quarter ending 30th June 2021. The results were taken on record by the Board of Directors at a meeting held 29 July.
After posting its financials from 2017 and its guidance for the year to come, it’s clear to see why Takeda needed to inject some growth into the company through its mega-merger with Shire.